1. Home
  2. DOMH vs APVO Comparison

DOMH vs APVO Comparison

Compare DOMH & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DOMH
  • APVO
  • Stock Information
  • Founded
  • DOMH 1967
  • APVO 2016
  • Country
  • DOMH United States
  • APVO United States
  • Employees
  • DOMH N/A
  • APVO N/A
  • Industry
  • DOMH Biotechnology: Pharmaceutical Preparations
  • APVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • DOMH Health Care
  • APVO Health Care
  • Exchange
  • DOMH Nasdaq
  • APVO Nasdaq
  • Market Cap
  • DOMH 8.8M
  • APVO 6.5M
  • IPO Year
  • DOMH N/A
  • APVO N/A
  • Fundamental
  • Price
  • DOMH $3.02
  • APVO $4.16
  • Analyst Decision
  • DOMH
  • APVO Strong Buy
  • Analyst Count
  • DOMH 0
  • APVO 1
  • Target Price
  • DOMH N/A
  • APVO $296.00
  • AVG Volume (30 Days)
  • DOMH 411.4K
  • APVO 52.2K
  • Earning Date
  • DOMH 03-31-2025
  • APVO 03-04-2025
  • Dividend Yield
  • DOMH N/A
  • APVO N/A
  • EPS Growth
  • DOMH N/A
  • APVO N/A
  • EPS
  • DOMH N/A
  • APVO N/A
  • Revenue
  • DOMH $12,589,000.00
  • APVO N/A
  • Revenue This Year
  • DOMH N/A
  • APVO N/A
  • Revenue Next Year
  • DOMH N/A
  • APVO N/A
  • P/E Ratio
  • DOMH N/A
  • APVO N/A
  • Revenue Growth
  • DOMH 1117.50
  • APVO N/A
  • 52 Week Low
  • DOMH $0.83
  • APVO $3.65
  • 52 Week High
  • DOMH $4.35
  • APVO $399.60
  • Technical
  • Relative Strength Index (RSI)
  • DOMH 83.11
  • APVO 37.34
  • Support Level
  • DOMH $1.34
  • APVO $3.77
  • Resistance Level
  • DOMH $4.35
  • APVO $4.47
  • Average True Range (ATR)
  • DOMH 0.44
  • APVO 0.30
  • MACD
  • DOMH 0.26
  • APVO 0.07
  • Stochastic Oscillator
  • DOMH 71.34
  • APVO 31.64

About DOMH Dominari Holdings Inc.

Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: